Authors
Latest:
Genomic Features of the 2015 Elizabethkingia OutbreakResearchers from Pasteur Institute, Paris, France, and the Centers of Disease Control and Prevention, examine the genomic features of the E. anophelis strain behind the 2015-2016 Wisconsin outbreak.
Latest:
New Line of HIV Treatment Identified for Patients Ineligible for EfavirenzA national clinical trial has found non-efavirenz antiretroviral therapy effective as a first-line treatment, which is good news for patients with HIV who are ineligible to usea the common drug.
Latest:
COVID-19 Complicates an Already Difficult Presentation of Infective EndocarditisFinal Diagnosis: Infective Endocarditis Due to Granulicatella adiacens and Streptococcus mitis.
Latest:
A Case of CNS Nocardia farcinica Presenting as Aphasia in an Immunocompetent HostQuick recognition is key to early initiation of treatment and long-term survival.
Latest:
Clinical Outcomes of Vancomycin Mono or Combination Therapy with a Beta-Lactam Against MRSA BacteremiaMethicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with high mortality.
Latest:
The Case of Late Aspergillus Fumigatus Infection of Implantable Cardioverter Defibrillator LeadsQuick action was needed against this very rare cause of fungal endocarditis.
Latest:
Daptomycin Dosing in Obesity: Consideration for a Fixed-Dose StrategyThis In the Literature piece considers a fixed-dose strategy for administering daptomycin in obese patients.
Latest:
Treating Outpatient Cystitis in the Era of Antimicrobial ResistanceWhat can clinicians do now that increasing resistance has limited oral treatment options for outpatient cystitis?
Latest:
Acute Bacterial Skin and Skin Structure Infections: A Modernized ApproachThe emergence of hospital- and community-based MRSA and other resistant gram-positive pathogens have made ABSSSI a critical public health challenge.
Latest:
What's New In 2024: From the CLSI Subcommittee on Antimicrobial Susceptibility TestingThe Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.
Latest:
Phase 3 Trial of Bulevirtide Yields Positive ResultsFor people living with chronic hepatitis D, the latest study results confirm the benefit of injections of this first-in-class entry inhibitor.
Latest:
Contagion® Interviews Pat Smith to Mark Lyme Disease Awareness MonthIn recognition of Lyme disease awareness month, Contagion® interviewed Pat Smith, president of Lyme Disease Association, Inc, to better understand current issues surrounding the diagnosis and treatment of Lyme disease.
Latest:
C Difficile Infection Is Associated With Higher Mortality Rates in Patients With CirrhosisClostridium difficile infection leads to higher rates of overall mortality among patients with cirrhosis compared to those who do not, according to a new study.
Latest:
Antiretroviral Safety in Pregnancy: Focus on Dolutegravir, Integrase Inhibitors, and Neural Tube DefectsThere has been increasing interest in the association between neural tube defects, dolutegravir, and integrase inhibitors as a class since 4 cases were reported in 2018.
Latest:
The Continued Search for Optimal Daptomycin Dosing Strategies in VRE Bloodstream InfectionsOptimal dosing of daptomycin is unknown, but study results suggest higher doses are required for successful clinical and microbiological outcomes.
Latest:
Implications of the 21st Century Cures Act on Antibiotic Drug DevelopmentExperts weigh in on what Congress is doing to tackle the threat of antibiotic resistance.
Latest:
How Does HIV Affect the Brain?Dr. Shibani Mukerji discusses how HIV affects the brain as part of a symposium at ID Week 2017.
Latest:
Exploring Primary Prophylaxis for Invasive Pulmonary AspergillosisInvasive aspergillosis affects up to 13% of immunocompromised patients who are in the hospital.
Latest:
Five Ways ID Clinicians Can Take On Antibiotic Resistance: Highlights From the CDC's Latest ReportA death from an antibiotic-resistant infection occurs about every 15 minutes in the United States. The CDC’s 2019 threat report dives into national infection estimates and actions we can take to combat this threat.
Latest:
Diagnosis and Treatment of Chronic Lyme Disease: A Complex IssueRecognition of chronic Lyme disease and the role of long-term antibiotic treatment for persistent symptoms continue to be controversial among researchers, providers, patients, and advocates.
Latest:
Effectiveness of Pertussis Vaccine May Wane Over Time, Study ShowsKaiser Permanente Northern California’s study shows that the pertussis vaccine weakens as time passes after a patient's most recent vaccination.
Latest:
Pfizer Foundation Donates Millions to Help Combat ZikaThe CDC Foundation and the Florida Department of Health have announced that the the Pfizer Foundation has donated millions to improve Zika response efforts.
Latest:
Outpatient Antimicrobial Stewardship: Field of Dreams or Land of Opportunity for Pharmacists?Relevant existing reports, though limited, demonstrated positive outcomes and suggest a promising space for pharmacy practice growth in outpatient antimicrobial stewardship.
Latest:
Diagnostic Stewardship: Beyond Managing Bloodstream InfectionsDiagnostic stewardship is a novel concept related to modifying the process of ordering, testing, and reporting with the goal of decreasing unnecessary testing and treatment, working upstream and synergistically with antimicrobial stewardship principles.
Latest:
COVID-19, SARS-CoV-2 and Pregnancy: Does the Past Predict the Present?Preliminary evidence indicates no direct evidence for intrauterine transmission of the SARS-CoV-2 virus from pregnant women with COVID-19 to their infants.
Latest:
Bacteriophage-Antibiotic Combinations: A Promising Alternative for Refractory Infections?Despite the initial abandonment of bacteriophages in most areas of the world, the era of antibiotic resistance has led to a resurgence of phage therapy in clinical practice.
Latest:
Intravenous Fosfomycin for Systemic Multidrug-Resistant InfectionsIntravenous (IV) fosfomycin offers a novel therapeutic option in the treatment of systemic multi-drug resistant (MDR) infections. Unanswered questions remain regarding its efficacy and specific role in our therapeutic arsenal.
Latest:
Shoutout to the Stewards: Holiday EditionContagion® radio is here to bring joy with every new antibiotic alert!
